Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
ST

NASDAQ · STRO

Sutro Biopharma, Inc.

Healthcare · Biotechnology

$9.94

Up+$0.43 (+4.52%)

Updated Nov 5, 2026, 2:50 AM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
83.52M
P/E ratio
-0.38
Dividend yield
0.00%
52-week range
$8.11 – $43.85
Volume
158.85K
Avg. volume
105.45K

Price performance · STRO

STRO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

STRO closed at $9.94 after 21 trading sessions, down 32.20% for the selected period.

Last close
$9.94
Period change
-32.20%
Period low
$8.87
Period high
$15.32
Daily close
View OHLC price history
STRO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$9.83$10.25$9.36$9.94158.85K
Nov 3, 2026$9.20$9.836$9.025$9.51127.76K
Nov 2, 2026$9.10$9.345$8.94$9.11147.92K
Oct 30, 2026$9.04$9.40$8.8019$9.10122.29K
Oct 29, 2026$9.36$9.755$9.08$9.14260.21K
Oct 28, 2026$8.69$9.305$8.46$9.29353.52K
Oct 27, 2026$8.87$9.14$8.44$8.87453.24K
Oct 26, 2026$9.32$9.428$8.11$8.885694.47K
Oct 23, 2026$10.22$10.293$9.16$9.33430.84K
Oct 22, 2026$10.69$10.93$10.00$10.29293.29K
Oct 21, 2026$11.62$11.80$10.75$10.79439.85K
Oct 20, 2026$11.25$11.70$11.11$11.54273.81K
Oct 19, 2026$11.01$11.46$10.75$11.255345.15K
Oct 16, 2026$11.47$11.47$10.585$10.94363.46K
Oct 15, 2026$10.54$11.65$10.51$11.46418.38K
Oct 14, 2026$10.99$11.305$10.36$10.52489.82K
Oct 13, 2026$13.11$13.185$10.84$11.01406.68K
Oct 12, 2026$14.08$14.2099$12.8275$13.28298.74K
Oct 9, 2026$15.31$15.415$14.05$14.27256.23K
Oct 8, 2026$14.46$16.205$14.40$15.32499.98K
Oct 7, 2026$14.24$15.78$14.01$14.66232.53K

Latest STRO news

The latest Smart Investors Daily articles mentioning STRO.

Stock researchCompany · Overview

STRO research

Overview

Company profile and research snapshot.

Company profile

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.86
Implied upside
—
Analysts
—
STRO recent ratings
DateFirmRatingTarget
Oct 15, 2026WedbushOutperform—
Aug 13, 2026CitizensMarket Outperform—
Aug 13, 2026WedbushOutperform—
May 28, 2026BarclaysOverweight—
May 15, 2026WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors

— STRO-006 is Sutro’s second wholly-owned ADC to enter the clinic in less than one year — — Initial clinical data expected in the second half of 2027 — SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase 1 trial of STRO-006 in patients with a range of

Yahoo · Oct 12, 2026

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 17th Annual World ADC Conference, taking place in San Diego, October 12-15, 2026. “Sutro's presence at World ADC this year reflects meaningful progress across our pipeline, from a plenary presentation on the early clinical saf

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By